

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. VPI/03-170 US

First Inventor Luc J. Farmer

Title INHIBITORS OF SERINE PROTEASES,
PARTICULARLY HCV NS3-NS4A PROTEASE

Express Mail Label No. EV 317 172 612 US

U.S. PTO
10/821793

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)

2. Applicant claims small entity status.
See 37 CFR 1.27.

3. Specification [Total Pages 108]

(preferred arrangement set forth below)

- Descriptive title of the invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

4. Drawing(s) (35 U.S.C. 113) [Total Sheets]

5. Oath or Declaration [Total Pages 3]

a. UNEXECUTED DECLARATION (original or copy)

b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)

i. DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 CFR 1.63(d)(2) and 1.33(b).

6. Application Data Sheet. See 37 CFR 1.76

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-part (CIP) of prior application No.:

Prior application information: Examiner _____ Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

 Customer Number or Bar Code Label

27916

or Correspondence address below

Name	Michael C. Badia Vertex Pharmaceuticals Incorporated				
Address	130 Waverly Street				
City	Cambridge	State	Massachusetts	Zip Code	02139-4242
Country	USA	Telephone	(617) 444-6417		Fax (617) 444-6483
Name (Print/Type)	Michael C. Badia			Registration No. (Attorney/Agent)	51,424
Signature				Date	April 9, 2004

Attorney Docket No.: VPI/03-170 US

Certificate Of Mailing Under 37 C.F.R. § 1.10

Express Mailing No. EV 317 172 612 US Date of Deposit: April 9, 2004

I hereby certify that the following documents:

1. Utility Transmittal for Patent Application;
2. Specification 108 pages (Desc. 76 pgs, Claims 31 pgs., Abstract 1pg); and
3. Unexecuted Declaration and Power of Attorney document (3 pages);
4. Return postcard receipt.

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the MS Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



(type or printed name of person mailing document(s))

Karen DiRocco

(signature of person mailing document(s))